DPI-3290 [(+)-3-((α-R)-α -((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl) -N-(3-fluorophenyl)-N-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 3, 2003, Pages 1227-1233

  Gengo, Peter J ^a   Pettit, Hugh O ^a   O'Neill, Scott J ^a   Su, Ying Fu ^a   McNutt, Robert ^a   Chang, Kwen Jen ^a  

^a Ardent Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N (3 FLUOROPHENYL) N METHYLBENZAMIDE; ALFENTANIL; BENZAMIDE DERIVATIVE; CARBON DIOXIDE; DPI 3290; FENTANYL; MORPHINE; MU OPIATE RECEPTOR; OPIATE AGONIST; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTERIAL GAS; ARTICLE; CARBON DIOXIDE TENSION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HYPERCAPNIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; STRUCTURE ACTIVITY RELATION; TAIL FLICK TEST;

ALFENTANIL; ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BENZAMIDES; CARBON DIOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE; NARCOTICS; OXYGEN; OXYGEN CONSUMPTION; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM;

EID: 0345167160     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.054429     Document Type: Article

References (26)

1. Alt A, Clark MJ, Woods JH, and Traynor JR (2002) Mu and delta opioid receptors active the same G-proteins in human neuroblastoma SH-SY5Y cells. Br J Pharmacol 135:217-225.
2. Chang K-J, Rigdon GC, Howard JL, and McNutt RW (1993) A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 267:852-857.
3. Chang K-J (1984) Opioid receptors: multiplicity and sequelae of ligand-receptor interactions, in The Receptors (Conn M ed) pp 1-81, Academic Press, New York.
4. Childers SR (1991) Opioid receptor-coupled second messenger systems. Life Sci 48:1991-2003.
5. Clotz MA and Nahata MC (1991) Clinical uses of fentanyl, sufentanil and alfentanil, Clin Pharm 10:581-593.
6. + conductance of DRG neurons and neuroblastoma x DRG neuron hybrid F11 cells. Brain Res 696:97-105.
7. Fan SF, Shen KF, and Crain SM (1993) μ and δ opioid agonists at low concentrations decrease voltage-dependent K currents in F11 neuroblastoma X DRG neuron hybrid cells via cholera toxin-sensitive receptors. Brain Res 605:214-220.
8. Gengo PJ, Pettit HO, O'Neill SJ, Wei K, McNutt R, and Chang K-J (2003) DPI-3290 [(+)-3-((α-R)-α -((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl-N-(3-fluorophenyl) -N-methylbenzamide)]. I. A mixed opioid agonist with potent antinociceptive activity. J Pharmacol Exp Ther 307:1221-1226.
9. He L and Lee NM (1998) Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. J Pharmcol Exp Ther 285:1181-1186.
10. Holder KA, Dougherty TB, and Chiang JS (1995) Postoperative pain management. Cancer Bulletin 47:43-51.
11. Inturrisi CE (1990) Opiate analgesic therapy in cancer pain, in Advances in Pain Research and Therapy (Forley KM ed) vol. 16, pp. 133-154, Raven Press, New York.
12. Jin W, Lee NM, Loh HH, and Thayer SA (1994) Opioids mobilize calcium from inositol 1,4,5-triphosphate-sensitive stores in NG108-15 cells. J Neurosci 14:1920-1929.
13. Law PY and Loh HH (1999) Regulation of opioid receptor activities. J Pharmacol Exp Ther 289:607-624.
14. Le Bars D, Gozariu M, and Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53:597-652.
15. Lee PHK, McNutt RW, and Chang K-J (1993) A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat. J Pharmacol Exp Ther 267:883-887.
16. Mason P (1999) Central mechanism of pain modulation. Curr Opin Neurobiol 9:436-441.
17. McGilliard KL and Takemori AE (1978) Antagonism by naloxone of narcotic-induced respiratory depression and analgesia. J Pharmacol Exp Ther 207:494-503.
18. 4] deltorphin in supraspinal antinociception and δ-opioid receptor binding. Br J Pharmacol 116:2931-2938.
19. O'Neill SJ, Collins MA, Pettit HO, McNutt RW, and Chang K-J (1997) Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. J Pharmacol Exp Ther 282:271-277.
20. Reisine T and Pasternak G (1993) Opioid analgesics and antagonists, in The Pharmacological Basis of Therapeutics (Molinof PB and Ruddon RW eds) vol. 1, pp 521-555, MacMillan, New York.
21. Rossi GC, Pasternak GW, and Bodnar RJ (1994) μ and δ Opioid synergy between the periaqueductal gray and rotro-ventral medulla. Brain Res 665:85-93.
22. Satoh M and Minami M (1995) Molecular pharmacology of the opioid receptors. Pharmacol Ther 86:343-364.
23. Schiller PW, Nguyen TMD, Weltrowska G, Wilkes BC, Lemieux C, and Chung NN (1992) Differential stereochemical requirements of μ vs δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc Natl Acad Sci USA 89:11871-11875.
24. Su YS, McNutt R, and Chang K-J (1998) Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J Pharmacol Exp Ther 287:815-823.
25. Wolozin BL and Pasternak GW (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci USA 78:6181-6185.
26. Wong CL (1992) The effect of naloxone on restraint-induced antinociception in mice. Methods Find Exp Clin Pharmacol 14:695-700.